Hester biosciences Limited has announced an earnings conference call to discuss its financial performance for the third quarter and nine months of fiscal year 2026. The company filed an official intimation with stock exchanges on January 23, 2026, informing investors about the scheduled teleconference.

Conference Call Details

The earnings discussion is scheduled for January 30, 2026, at 2:00 PM Indian Standard Time. This investor interaction will take place following the announcement of financial results for the quarter and nine months period ended December 31, 2025.

Management Representation

The conference call will feature senior management personnel who will present the company's financial performance and address investor queries. The management team participating in the call includes key executives from various operational areas.

Regulatory Compliance

The earnings conference call announcement was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company submitted the intimation to both BSE Limited and National Stock Exchange of India Limited on January 23, 2026.

ICICI Securities is coordinating the investor interaction session and has provided registration details for participants. The brokerage firm has designated multiple contact persons to assist investors with call-related queries and clarifications.

Coordination and Contact Information

ICICI Securities has appointed Mr. Jaideep Goswami, Head of Equities, as the primary call coordinator. Additional support staff including Mr. Abdulkader Puranwala, Mr. Rushad Kapadia, Ms. Seema Sehgal, and Ms. Minali Ginwala have been designated to handle investor queries and provide technical assistance for the conference call participation.

Hester Biosciences Limited , a prominent player in the biosciences sector, has announced a significant change in its top management. The company has appointed Mr. Ashish Desai as its new Chief Financial Officer (CFO) and Key Managerial Personnel, effective from 20 November 2025.

Appointment Details

The appointment of Mr. Desai was approved by the Board of Directors through a circulation of resolution, based on recommendations from both the Nomination and Remuneration Committee and the Audit Committee. This decision aligns with the company's commitment to strengthening its financial leadership.

About Ashish Desai

Mr. Desai brings a wealth of experience to his new role:

Implications for Hester Biosciences

Mr. Desai's appointment as CFO is expected to bring valuable financial acumen to Hester Biosciences. His extensive experience in various aspects of finance, including his tenure as Group Finance Controller within the company, positions him well to lead the financial operations of Hester Biosciences.

This strategic move comes at a time when companies are increasingly focusing on robust financial management and strategic financial planning. Mr. Desai's appointment may signal Hester Biosciences' intent to further strengthen its financial processes and potentially explore new growth opportunities.

As Hester Biosciences continues to navigate the dynamic biosciences sector, Mr. Desai's leadership in the finance department will be crucial in supporting the company's overall strategic objectives and maintaining its competitive edge in the market.

The company has complied with all necessary regulatory disclosures regarding this appointment, as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.